Collard D, et al. - In patients with type 2 diabetes mellitus randomized to intensive (target systolic blood pressure of < 120 mm Hg) or standard antihypertensive (< 140 mm Hg) treatment in the ACCORD-BP trial, researchers focused on the link between a serum creatinine increase after initiation of antihypertensive therapy and adverse clinical outcomes. All-cause mortality, major cardiovascular events, and renal failure were assessed as a combined end point (primary outcome). In both treatment groups, a higher risk of clinical adverse outcomes was observed in relation to a > 30% serum creatinine increase after adjusting for possible confounders; however, the magnitude of this effect was similar. Overall, clinicians were recommended not to directly reduce antihypertensive medication in patients with type 2 diabetes mellitus who have a > 30% serum creatinine increase that coincides with lower blood pressure values.